- 期刊
復發性卵巢癌的治療：癌康定(Hycamtin-Topotecan)使用現況
The Role of Topotecan in the Treatment of Recurrent Ovarian Cancer
摘要
卵巢癌通常不易早期診斷，75%的卵巢癌患者發現時都已是晚期了，手術合併化學治療可達到75%的臨床上完全緩解，但這些完全緩解的病人之後有50~75%會復發。癌康定(Hycamtin-Topotecan)是喜樹鹼(Camptothecin)的半合成衍生物，其為DNA合成過程中Topoisomerase type I的抑制劑，使腫瘤細胞無法複製，具有高抗癌性及低毒性，因此廣泛被使用於復發性的卵巢癌，然而，傳統五天的給藥方式每天給予1.25~1.5mg/平方公尺在臨床使用上有些個案呈現嚴重的骨髓抑制，造成病患生活品質的不便與醫師給藥的困擾。近年來許多文獻報告每週給藥的方式可以大大降低副作用且增加治療的可行性。
並列摘要
It is difficult to diagnose ovarian cancer, which is an asymptomatic disease at early stage; on the other hand, 75% of the patients were diagnosed at advanced stage. Although surgery followed by chemotherapy can achieve clinical complete remission as high as 75 %, more than half of these patients will eventually suffer from recurrence. Topotecan is the semi-synthetic product from the extract of camptothecin. It acts as the type I topoisomerase inhibitor during the synthesis of DNA and cell proliferation. Moreover, it helps to inhibit the duplication of tumor cell. Due to its highly antitumor effect and low toxicity, topotecan is now generally used in the treatment of recurrent ovarian cancer. However, the traditional 5-day schedule of topotecan 1.25~1.5 mg/m^2 /day will result in severe myelosupression in some cases, which affect the quality of life and schedule of drug prescription. Current studies revealed the feasibility of weekly administration method, dramatically decreasing the incidence of side effects and increasing the availability of treatment.